NVST vs. SYK: Which Stock Should Value Investors Buy Now?

Core Viewpoint - Investors in the Medical - Products sector should consider Envista (NVST) and Stryker (SYK) for potential value investment opportunities [1] Group 1: Zacks Rank and Analyst Outlook - Envista has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision activity compared to Stryker, which has a Zacks Rank of 3 (Hold) [3] - The improving analyst outlook for NVST suggests a more positive sentiment among analysts [3] Group 2: Valuation Metrics - NVST has a forward P/E ratio of 19.16, significantly lower than SYK's forward P/E of 26.00, indicating NVST may be undervalued [5] - The PEG ratio for NVST is 1.07, while SYK's PEG ratio is 2.50, suggesting NVST has a better growth-to-price ratio [5] - NVST's P/B ratio is 1.16, compared to SYK's P/B of 6.19, further indicating NVST's relative undervaluation [6] Group 3: Value Grades - Based on various valuation metrics, NVST holds a Value grade of B, while SYK has a Value grade of C, making NVST a more attractive option for value investors [6]